Skip to main content

Table 4 Comparison between the patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s in the 94 patients with NVR of past IFN treatment

From: PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients

 

Patients with Vs ≧ 1.55 m/s

Patients with Vs < 1.55 m/s

Comparison between patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s

Multiple regression analysis for factors associated with ≧ 1.55 m/s

(n = 45)

(n = 49)

Odds ratio (95% confidence interval)

p

Age (yrs)

64.3±9.4

57.7±10.9

P = 0.0026

1.03 (1.03 - 1.13)

p = 0.0023

Gender (male/female)

18/27

21/28

NS

 

NS

BMI (kg/m2)

23.7±3.8

22.2±2.8

P = 0.0274

1.20 (1.04 - 1.39)

p = 0.0156

PNPLA3 (GG/CC・CG)

10/35

9/40

NS

  

AST (IU/L)

59.6±22.0

51.7±63.9

NS

  

ALT (IU/L)

58.6±31.2

62.8±98.8

NS

  

γ-GTP (IU/L)

57.2±37.1

62.1±122.7

NS

  

Albumin (g/dL)

3.9±0.7

4.4±0.3

p < 0.0001

  

Total bilirubin (mg/dL)

0.9±0.3

1.0±1.4

NS

  

Platelet count (x104/μL)

11.1±4.4

16.7±5.1

p < 0.0001

  

Prothrombin time (%)

88.5±14.1

104.0±16.5

p < 0.0001

  

Hyaluronic acid (ng/mL)

305.2±229.7

89.3±170.5

p < 0.0001

  

α-fetoprotein (ng/mL)

20.1±18.0

4.9±3.6

p < 0.0001

  

PIVKA-II(mAU/mL)

23.5±13.9

19.9±9.3

NS

  

HCV genotype (1/2/3)

40/4/1

39/10/0

NS

  

HCV RNA (log IU/mL)

6.3±0.9

6.0±1.3

NS

  

Velocity of shear wave (m/s)

2.20±0.50

1.23±0.16

p < 0.0001

  

Hepatocellular carcnoma (present/absent)

14/31

3/46

P = 0.0017

  
  1. NVR, non-virological response; IFN, interferon; Vs, velocity of shear wave; BMI, body mass index; PNPLA3, patatin-like phospholipase domain-containing 3; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II ; NS, not significant.